139 related articles for article (PubMed ID: 15849223)
41. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma.
Quan W; Brick W; Vinogradov M; Taylor WC; Khan N; Burgess R
Cancer Biother Radiopharm; 2004 Jun; 19(3):350-4. PubMed ID: 15285881
[TBL] [Abstract][Full Text] [Related]
42. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
43. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G; Madeddu C; Gramignano G; Lusso MR; Mocci M; Massa E; Ferreli L; Astara G; Macciò A; Serpe R
J Exp Ther Oncol; 2003; 3(4):205-19. PubMed ID: 14567291
[TBL] [Abstract][Full Text] [Related]
44. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.
Favrot M; Floret D; Michon J; Negrier S; Bouffet E; Coze C; Gaspard M; Cochat P; Thiesse P; Andreu G
Cancer Treat Rev; 1989 Jun; 16 Suppl A():129-42. PubMed ID: 2670209
[TBL] [Abstract][Full Text] [Related]
45. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Pein F; Pinkerton R; Tournade MF; Brunat-Mentigny M; Levitt G; Margueritte G; Rubie H; Sommelet D; Thyss A; Zücker JM
J Clin Oncol; 1993 Aug; 11(8):1478-81. PubMed ID: 8393095
[TBL] [Abstract][Full Text] [Related]
46. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
Meazza C; Cefalo G; Massimino M; Daolio P; Pastorino U; Scanagatta P; Morosi C; Podda M; Ferrari A; Terenziani M; Spreafico F; Casanova M; Parafioriti A; Collini P; Gandola L; Bastoni S; Biassoni V; Schiavello E; Chiaravalli S; Puma N; Bergamaschi L; Luksch R
Med Oncol; 2017 Nov; 34(12):191. PubMed ID: 29094224
[TBL] [Abstract][Full Text] [Related]
47. [Continuous infusion of natural interleukin 2 (n IL-2) in treatment of malignant diseases: phase I study].
Lenz HJ; Brunner T; Dopfer R; Schlag H; Ehninger G
Onkologie; 1990 Dec; 13(6):429-33. PubMed ID: 2092279
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
Marina NM; Pappo AS; Parham DM; Cain AM; Rao BN; Poquette CA; Pratt CB; Greenwald C; Meyer WH
J Clin Oncol; 1999 Jan; 17(1):180-90. PubMed ID: 10458232
[TBL] [Abstract][Full Text] [Related]
49. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
50. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
51. Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumors.
Kalwak K; Ussowicz M; Gorczyńska E; Turkiewicz D; Toporski J; Dobaczewski G; Latos-Grazyńska E; Ryczan R; Noworolska-Sauren D; Chybicka A
J Interferon Cytokine Res; 2003 Apr; 23(4):173-81. PubMed ID: 12856329
[TBL] [Abstract][Full Text] [Related]
52. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
[TBL] [Abstract][Full Text] [Related]
53. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.
Geoerger B; Doz F; Gentet JC; Mayer M; Landman-Parker J; Pichon F; Chastagner P; Rubie H; Frappaz D; Le Bouil A; Gupta S; Vassal G
J Clin Oncol; 2008 Sep; 26(27):4394-400. PubMed ID: 18802151
[TBL] [Abstract][Full Text] [Related]
54. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
[TBL] [Abstract][Full Text] [Related]
55. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
[TBL] [Abstract][Full Text] [Related]
56. Changes in laboratory results for cancer patients treated with interleukin-2.
Huang CM; Elin RJ; Ruddel M; Sliva C; Lotze MT; Rosenberg SA
Clin Chem; 1990 Mar; 36(3):431-4. PubMed ID: 2311209
[TBL] [Abstract][Full Text] [Related]
57. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
58. [Phase I trial of a recombinant human interleukin 2. Results in patients with disseminated solid tumors].
Tursz T; Dorval T; Berthaud P; Jouve M; Avril MF; Garcia-Giralt E; Le Chevalier T; Spielmann M; Sevin D; Palangie T
Presse Med; 1991 Feb; 20(6):250-4. PubMed ID: 1826163
[TBL] [Abstract][Full Text] [Related]
59. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
[TBL] [Abstract][Full Text] [Related]
60. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.
Merchant MS; Wright M; Baird K; Wexler LH; Rodriguez-Galindo C; Bernstein D; Delbrook C; Lodish M; Bishop R; Wolchok JD; Streicher H; Mackall CL
Clin Cancer Res; 2016 Mar; 22(6):1364-70. PubMed ID: 26534966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
